Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01772641 · ClinicalTrials.gov registry record · Phase 4
A Smoking Intervention Study Using Scheduled Gradual Reduction With Varenicline to Help With Cessation
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Terminated
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT01772641 is a Phase 4 study that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 32 participants.
The verdict
NCT01772641, a Phase 4 study, was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study has three main aims. Aim 1: To provide initial data on the efficacy of combined Scheduled Gradual Reduction (SGR) and Varenicline (VN) for smoking cessation, by assessing abstinence and levels of smoking at 2 time points (4 and 12 weeks post quit). Aim 2: To explore the possibility that SGR+VN will be particularly efficacious among smokers with higher background levels of Cue Reactivity (CR), as assessed at the start of the study, using a classic experimental smoking CR paradigm. Aim 3: To explore possible mechanisms underlying the effects of SGR+VN, by assessing potential mediators (i.e., self-efficacy, cue-induced cravings) of treatment effects.
Interventions
- OTHER Scheduled Gradual Reduction + Varenicline
- OTHER Scheduled Gradual Reduction + Placebo Drug
- OTHER Basic Advice + Varenicline
- OTHER Basic Advice + Placebo Drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01772641
The ClinicalTrials.gov registry entry for NCT01772641 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Scheduled Gradual Reduction + Varenicline is the first listed.
NCT01772641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01772641 about?
NCT01772641 is a clinical study titled "A Smoking Intervention Study Using Scheduled Gradual Reduction With Varenicline to Help With Cessation". This study has three main aims. Aim 1: To provide initial data on the efficacy of combined Scheduled Gradual Reduction (SGR) and Varenicline (VN) for smoking cessation, by assessing abstinence and levels of smoking at 2 time points (4 and 12 weeks post quit). Aim 2: To explore the possibility that S...
What is the current status of trial NCT01772641?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2012-12. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01772641?
The interventions under investigation include: Scheduled Gradual Reduction + Varenicline (OTHER), Scheduled Gradual Reduction + Placebo Drug (OTHER), Basic Advice + Varenicline (OTHER), Basic Advice + Placebo Drug (OTHER).
Who is sponsoring clinical trial NCT01772641?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.